Not a SARM — a PPAR-delta agonist. Clinical development was permanently abandoned after animal studies demonstrated cancer development at all tested doses across multiple species. Despite this, it remains widely circulated.
Clinical development of Cardarine was permanently abandoned after animal carcinogenicity studies demonstrated accelerated tumor development at every dose tested across multiple organ systems. There is no safe or established performance use case. The endurance and fat oxidation effects that attracted performance interest are real at a mechanistic le...
Cardarine does not have a responsible stacking context. In practice it appears in stacks with SARMs and traditional anabolics for the endurance and lipid management effects. This does not make those combinations appropriate. It makes them stacks that include a compound with documented cancer risk in animal models at all tested doses. The absence of...
GlaxoSmithKline permanently abandoned Cardarine development after two-year carcinogenicity studies showed accelerated tumor development across multiple organ systems at every dose tested in every animal model studied. There is no safe dose established, no long-term human data, and no approved use. T...